Esperion Therapeutics ESPR Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's available-for-sale debt securities - amortized cost?
- Esperion Therapeutics (ESPR) reported available-for-sale debt securities - amortized cost of $124.21M in Q1 2026.
- How has Esperion Therapeutics's available-for-sale debt securities - amortized cost changed year-over-year?
- Esperion Therapeutics's available-for-sale debt securities - amortized cost increased by 40.4% year-over-year, from $88.46M to $124.21M.
- What is the long-term trend for Esperion Therapeutics's available-for-sale debt securities - amortized cost?
- Over 5 years (2020 to 2025), Esperion Therapeutics's available-for-sale debt securities - amortized cost has grown at a -13.6% compound annual growth rate (CAGR), from $281.78M to $135.64M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.